Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Biochemical Society Transactions

• Publication date

  2011-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1042/BST0390891PMID 21787319
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.

  2012cited by this paper
• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• β-Amyloid impairs axonal BDNF retrograde trafficking.

  2011cited by this paper
• CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.

  2010cited by this paper
• GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

  2010cited by this paper
• Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.

  2010cited by this paper
• P3‐456: Galantamine versus nootropic medication in the treatment of Alzheimer's disease: An observational trial under naturalistic conditions

  2010cited by this paper
• Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

  2010cited by this paper
• Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases

  2010cited by this paper
• Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.

  2010cited by this paper
• New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

  2010cited by this paper
• Brain-derived neurotrophic factor in neurodegenerative diseases

  2009cited by this paper
• Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease

  2009cited by this paper
• Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration

  2009cited by this paper
• Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders?

  2009cited by this paper
• SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL

  2009cited by this paper
• Development of a non invasive NGF-based therapy for Alzheimer's disease.

  2009cited by this paper
• Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease

  2009cited by this paper
• Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

  2009cited by this paper
• Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice

  2009cited by this paper
• A profile of impaired insulin degradation in relation to late‐life cognitive decline: A preliminary investigation

  2009cited by this paper
• Clinical gene therapy using recombinant adeno-associated virus vectors

  2008cited by this paper
• The insulin‐regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus – potential role in modulation of glucose uptake in neurones?

  2008cited by this paper
• Intranasal insulin improves cognition and modulates β-amyloid in early AD

  2008cited by this paper
• Intranasal insulin improves cognition and modulates β-amyloid in early AD

  2008cited by this paper
• Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

  2008cited by this paper
• Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults

  2008cited by this paper
• Adeno‐associated virus‐mediated gene delivery approaches for the treatment of CNS disorders

  2008cited by this paper
• Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke Model

  2007cited by this paper
• Incretins and their role in the management of diabetes

  2007cited by this paper
• Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.

  2007cited by this paper
• Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

  2007cited by this paper
• Effects of Subchronic Treatment With the Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist, N-AcGIP, on Glucose Homeostasis in Streptozotocin-Induced Diabetes

  2007cited by this paper
• Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?

  2007cited by this paper
• Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes

  2007cited by this paper
• Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model.

  2007cited by this paper
• Common pathological processes in Alzheimer disease and type 2 diabetes: a review.

  2007cited by this paper
• Practical issues in stem cell therapy for Alzheimer's disease.

  2007cited by this paper
• Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism.

  2006cited by this paper
• Nerve Growth Factor, Neural Stem Cells and Alzheimer’s Disease

  2006cited by this paper
• Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus

  2006cited by this paper
• Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease

  2006cited by this paper
• Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

  2005cited by this paper
• Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus.

  2005cited by this paper
• Distribution and cellular localization of insulin‐regulated aminopeptidase in the rat central nervous system

  2005cited by this paper
• Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.

  2005cited by this paper
• Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies

  2005cited by this paper
• Hope for AD with NGF gene-therapy trial.

  2005cited by this paper
• Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus

  2005cited by this paper
• Treatment of insulin resistance in diabetes mellitus.

  2004cited by this paper
• Neurodegenerative disorders associated with diabetes mellitus

  2004cited by this paper
• Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

  2004cited by this paper
• Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans.

  2004cited by this paper
• VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

  2004cited by this paper
• Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease.

  2004cited by this paper
• Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus.

  2004cited by this paper
• Insulin-like growth factor-I, cognition and brain aging.

  2004cited by this paper
• The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease.

  2004cited by this paper
• Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface.

  2004cited by this paper
• Insulin and the insulin receptor in experimental models of learning and memory.

  2004cited by this paper
• Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis.

  2004cited by this paper
• Hyperinsulinemia and risk of Alzheimer disease

  2004cited by this paper
• In vitro study of GDNF release from biodegradable PLGA microspheres.

  2004cited by this paper
• Insulin-like growth factor I and Alzheimer´s disease: therapeutic prospects?

  2004cited by this paper
• Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.

  2004cited by this paper
• Pharmacological Agents That Directly Modulate Insulin Secretion

  2003cited by this paper
• Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

  2003cited by this paper
• Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation

  2003cited by this paper
• Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo.

  2002cited by this paper
• Foxa2 Controls Pdx1 Gene Expression in Pancreatic β-Cells In Vivo

  2002cited by this paper
• A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

  2002cited by this paper
• Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

  2000cited by this paper
• Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells.

  2000cited by this paper
• Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats.

  2000cited by this paper
• Leptin Induces Insulin-like Signaling That Antagonizes cAMP Elevation by Glucagon in Hepatocytes*

  2000cited by this paper
• Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization

  2000cited by this paper
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

  2000cited by this paper
• Cognition and synaptic plasticity in diabetes mellitus.

  2000cited by this paper
• Synaptic plasticity and learning and memory: LTP and beyond

  1999cited by this paper
• Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

  1999cited by this paper
• Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.

  1999cited by this paper
• Calcium- and activity-dependent synaptic plasticity.

  1999cited by this paper
• A family of cAMP-binding proteins that directly activate Rap1.

  1998cited by this paper
• Recruitment of functional GABAA receptors to postsynaptic domains by insulin

  1997cited by this paper
• Models of Alzheimer's disease: cellular and molecular aspects.

  1997cited by this paper
• Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates.

  1997cited by this paper
• Amyloid, the presenilins and Alzheimer's disease.

  1997cited by this paper
• Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites

  1995cited by this paper
• Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants

  1994cited by this paper
• Activation of a Large‐conductance Ca2+‐Dependent K+ Channel by Stimulation of Glutamate Phosphoinositide‐coupled Receptors in Cultured Cerebellar Granule Cells

  1991cited by this paper
• Alzheimer’s Dementia

  1985cited by this paper

• Large-Scale Identification of Novel Protein Biomarkers and Therapeutic Targets in Heart and Brain Disease

  2026cites this paper
• Rock inhibitors in Alzheimer’s disease

  2025cites this paper
• Production, characterization, and in vitro evaluation of anti-Alzheimer's Memantine/Donepezil/Metformin-loaded PVA/PEO composite nanofibers by pressurized gyration

  2024cites this paper
• Shared whole environmental etiology between Alzheimer’s disease and age-related macular degeneration

  2024cites this paper
• Sonic Hedgehog Signalling Pathway Contributes in Age-Related Disorders and Alzheimer's Disease.

  2024cites this paper
• Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer’s disease

  2023cites this paper
• Metabolic Overlap between Alzheimer’s Disease and Metabolic Syndrome Identifies the PVRL2 Gene as a New Modulator of Diabetic Dyslipidemia

  2023cites this paper
• Systemic Metabolism and Mitochondria in the Mechanism of Alzheimer’s Disease: Finding Potential Therapeutic Targets

  2023cites this paper
• PP1γ regulates neuronal insulin signaling and aggravates insulin resistance leading to AD-like phenotypes

  2023cites this paper
• AdipoRon induces AMPK activation and ameliorates Alzheimer's like pathologies and associated cognitive impairment in APP/PS1 mice.

  2022cites this paper
• Influence of Genetic and Cardiometabolic Risk Factors in Alzheimer's Disease.

  2022cites this paper
• Salivary Biomarkers Associated with Psychological Alterations in Patients with Diabetes: A Systematic Review

  2022cites this paper
• GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

  2022cites this paper
• Elevated Peripheral Brain-Derived Neurotrophic Factor Level Associated With Decreasing Insulin Secretion May Forecast Memory Dysfunction in Patients With Long-Term Type 2 Diabetes

  2022cites this paper
• Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development.

  2022cites this paper
• Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment.

  2022cites this paper
• A Negative Energy Balance Is Associated with Metabolic Dysfunctions in the Hypothalamus of a Humanized Preclinical Model of Alzheimer’s Disease, the 5XFAD Mouse

  2021cites this paper
• Changes in Plasma Metabolome Profiles Following Oral Glucose Challenge among Adult Chinese

  2021cites this paper
• Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders

  2021cites this paper
• Degree Adjusted Large-Scale Network Analysis Reveals Novel Putative Metabolic Disease Genes

  2021cites this paper
• Potential of Sorghum Polyphenols to Prevent and Treat Alzheimer’s Disease: A Review Article

  2021cites this paper
• Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

  2021cites this paper
• Brain insulin resistance: role in neurodegenerative disease and potential for targeting

  2020influential citation
• Neuroinflammation, microglial activation, and glucose metabolism in neurodegenerative diseases.

  2020cites this paper
• Association of mild cognitive impairment and metabolic syndrome in patients with hypertension.

  2020cites this paper
• Caveolin: A New Link Between Diabetes and AD

  2020cites this paper
• Does hyperglycemia downregulate glucose transporters in the brain?

  2020cites this paper
• The potential role of nanoyttria in alleviating oxidative stress biomarkers: Implications for Alzheimer's disease therapy.

  2020cites this paper
• Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.

  2020cites this paper
• The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases

  2020cites this paper
• Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimer’s Disease

  2019cites this paper
• Protective effect of incretin aganist age-related disease.

  2019cites this paper
• Title: Biochemical linkage of type 2 diabetes mellitus and Alzheimer’s disease

  2019cites this paper
• The Metabolic Ghetto: An Evolutionary Perspective on Nutrition, Power Relations and Chronic Disease

  2019cites this paper
• The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration

  2019cites this paper
• Investigation of the Effect of Quercetin on Neurological Alterations During Type 2 Diabetes Mellitus in Swiss Albino Mice

  2019cites this paper
• Getting to the Heart of Alzheimer Disease

  2019cites this paper
• Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer’s Disease

  2019cites this paper
• Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis.

  2018cites this paper
• Cellular responses to amyloid-beta protofibrils : Focus on astrocytes, extracellular vesicles and antibody treatment

  2018cites this paper
• Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease

  2018influential citation
• Persistent organic pollutants (POPs): a sneaky culprit of chronic disease

  2018cites this paper
• Influence of Magnetic Fields and their Characteristics on cortical Excitability. Study on healthy adults and pathological aging

  2018influential citation
• Periodontal disease exacerbates Alzheimer's disease

  2018cites this paper
• The role of melatonin in the onset and progression of type 3 diabetes

  2017cites this paper
• The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer’s Disease, Based on a Mechanistic Target of Rapamycin Pathway

  2017cites this paper
• A novel dual GLP‐1/GIP receptor agonist alleviates cognitive decline by re‐sensitizing insulin signaling in the Alzheimer icv. STZ rat model

  2017cites this paper
• A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer’s Disease

  2017cites this paper
• The quantification of blood-brain barrier disruption using dynamic contrast-enhanced magnetic resonance imaging in aging rhesus monkeys with spontaneous type 2 diabetes mellitus

  2017cites this paper
• Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.

  2017cites this paper
• Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players.

  2017cites this paper
• Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice

  2017cites this paper
• Cigarette smoke and related risk factors in neurological disorders: An update.

  2017cites this paper
• Effects of butylphthalide on cognitive decline in diabetic rats.

  2017cites this paper
• Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease.

  2017cites this paper
• The blood‐brain barrier fatty acid transport protein 1 (FATP1/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport

  2017cites this paper
• Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons.

  2017cites this paper
• Reproducibility of Single-Pulse, Paired-Pulse, and Intermittent Theta-Burst TMS Measures in Healthy Aging, Type-2 Diabetes, and Alzheimer’s Disease

  2017influential citation
• Drug Repositioning for Alzheimer’s Disease Based on Systematic ‘omics’ Data Mining

  2016cites this paper
• Inflammasomes link vascular disease with neuroinflammation and brain disorders

  2016cites this paper
• Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

  2016cites this paper
• Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

  2016cites this paper
• Urtica dioica modulates hippocampal insulin signaling and recognition memory deficit in streptozotocin induced diabetic mice

  2016cites this paper
• Chronic type 2 diabetes reduces the integrity of the blood-brain barrier by reducing tight junction proteins in the hippocampus

  2016cites this paper
• Depression mediates impaired glucose tolerance and cognitive dysfunction: A neuromodulatory role of rosiglitazone.

  2016cites this paper
• Anti‐diabetic and neuroprotective effects of pancreatic islet transplantation into the central nervous system

  2016cites this paper
• Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy

  2016cites this paper
• Urtica dioica leaves modulates hippocampal smoothened-glioma associated oncogene-1 pathway and cognitive dysfunction in chronically stressed mice.

  2016cites this paper
• Identification of Shared Molecular Pathways and Networks between Alzheimer's Disease and Type 2 Diabetes

  2016cites this paper
• Consequences of Intracellular Amyloid in Vascular System

  2016cites this paper
• Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: therapeutic implications /

  2016cites this paper
• Alzheimer’s Disease and “Right-to-Work” Laws

  2016cites this paper
• Streptozotocin induced Alzheimer's disease like changes and the underlying neural degeneration and regeneration mechanism

  2015cites this paper
• Impact of cigarette smoke extract and hyperglycemic conditions on blood–brain barrier endothelial cells

  2015influential citation
• Insulin resistance-induced hyperglycemia decreased the activation of Akt/CREB in hippocampus neurons: Molecular evidence for mechanism of diabetes-induced cognitive dysfunction.

  2015cites this paper
• Effects of Acute Administration of Urtica dioica on the Novel Object- Recognition Task in Mice

  2015cites this paper
• Age-Related Decrease in Glucagon-Like Peptide-1 in Mouse Prefrontal Cortex but Not in Hippocampus Despite the Preservation of Its Receptor

  2015cites this paper
• Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

  2015influential citation
• Insulin resistance and cognitive dysfunction.

  2015cites this paper
• Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPKSer-485 Phosphorylation*

  2015cites this paper
• Intranasal delivery: circumventing the iron curtain to treat neurological disorders

  2015cites this paper
• Ocular nerve growth factor administration counteracts the impairment of neural precursor cell viability and differentiation in the brain subventricular area of rats with streptozotocin‐induced diabetes

  2015cites this paper
• The Diabetic Brain and Dementia

  2015cites this paper
• Neuroprotective effects of geniposide on Alzheimer’s disease pathology

  2015cites this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.

  2015cites this paper
• Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease.

  2015cites this paper
• Characterization of prefrontal cortex microstructure and antioxidant status in a rat model of neurodegeneration induced by aluminium chloride and multiple low-dose streptozotocin

  2015cites this paper
• Role of insulin resistance in Alzheimer’s disease

  2015cites this paper
• Cerebrospinal Fluid Levels of a 20–22 kDa NH2 Fragment of Human Tau Provide a Novel Neuronal Injury Biomarker in Alzheimer's Disease and Other Dementias

  2014cites this paper
• LEPTIN SIGNALLING IN THE HIPPOCAMPUS – MEMORY MODULATION

  2014cites this paper
• On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.

  2014cites this paper
• Diabetes of the brain: computational approaches and interventional strategies.

  2014cites this paper
• Geniposide Ameliorates Learning Memory Deficits, Reduces Tau Phosphorylation and Decreases Apoptosis via GSK3β Pathway in Streptozotocin‐Induced Alzheimer Rat Model

  2014cites this paper
• [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].

  2014cites this paper
• Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.

  2014cites this paper
• A Predictive Model for Dementia Risk in Elderly Adults with Prediabetes

  2014influential citation
• Comorbidities disorders and Alzheimer's disease = Zaburzenia i schorzenia współistniejące z chorobą Alzheimera

  2014cites this paper
• Comorbidities disorders and Alzheimer's disease

  2014cites this paper
• Effects of insulin gene dosage on body weight and glucose homeostasis

  2014cites this paper
• Análogos del glucagon-like peptide-1 (GLP-1): ¿una nueva estrategia de tratamiento para la enfermedad de Alzheimer?

  2014cites this paper